Skip to main content
. 2019 Mar 7;8(4):1540–1550. doi: 10.1002/cam4.2042

Figure 4.

Figure 4

Effect of ruxolitinib on IL10, CXCL10, and CXCL1. IL10, CXCL10, and CXCL1 were measured in plasma from blood at day 1 and day 21 of a treatment cycle (left panels) and also in plasma from marrow aspirates obtained at C1D1 and CD3D21 (right panels). Each line represents results for an individual patient. *P < 0.05